Evaluation of the Safety and Tolerability of Prucalopride in Constipated Elderly Subjects Living in a Nursing Facility

This is a multicenter, Phase II, dose-escalation trial with a 4 week double-blind, placebo-controlled treatment period. There will be four treatment cohorts (0.5 mg, 1 mg, 2 mg, or 4 mg) with 25 subjects in each. The first cohort of 25 subjects will be randomly assigned to receive either 0.5 mg R108512 or placebo in a 4 to 1 ratio, respectively, for four weeks. After two weeks of treatment, the safety and tolerability of this dose will be evaluated for each subject by an independent (external) safety committee. If, at the completion of treatment, the safety committee grants approval to proceed to a higher dose, the second cohort will be randomly assigned to receive either 1 mg R108512 or placebo for four weeks. In a likewise manner, each dose will be evaluated for safety and tolerability before the next cohort will be treated with a higher dose. No subject can participate in more than one treatment cohort.

Subjects will be instructed not to change their diet or lifestyle during the trial. Subjects will be allowed to continue the use of routine stool softeners and fiber supplements during the trial; however, all existing stimulant or osmotic laxative medication will be withdrawn. If, during the trial, the subject does not have a complete bowel movement for three or more consecutive days, he/she will be allowed the use of his/her usual stimulant or osmotic laxative or an enema as a rescue medication. No laxatives or enemas should be used within the 24 hours before and 24 hours after the start of double-blind treatment.

Inclusion criteria

• Male and female patients at least 65 years of age (no upper age limit).
• History of constipation. i.e., the patient should have received any treatment for constipation at any time during the 4 weeks (28 days) preceding entry into the study, including fibre/bulk forming supplements.
• The patient had to live in a nursing facility.
• The patient had to be clinically stable.
• The patient had to be able to take oral medications.
• The patient had to be continent of bowels the majority of time.
• The patient had to be able to reliably communicate AEs.
• The patient had to provide informed consent, signed by the patient or legally acceptable representative and by the investigator.

Exclusion criteria

• Patients who were known to be HIV positive or who had AIDS.
• Patients who were being actively treated with Propulsid (cisapride) or cancer chemotherapy other than hormonal agents.
• Patients with significantly impaired renal function, i.e., creatinine clearance <30 mL/min using the Cockcroft and Gault formula:

Males: CLCR = [(140-age) x (weight in kg)] / 72 x (SCR).

Females: CLCR = male value x 0.85

Because the calculated value for creatinine clearance could be artificially high when serum creatinine concentrations were very low, patients with a serum creatinine <0.5 mg/dL were excluded from the study.

• Patients who received an investigational drug in the 30 days preceding the study.
• Patients who had previously received either R093877 or R108512.